DDInter806 DDInter899
An acyclovir analog that is a potent inhibitor of the Herpesvirus family including cytomegalovirus. Ganciclovir is used to treat complications from AIDS-associated cytomegalovirus infections.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Ganciclovir {u} (Compound) resembles {v} (Compound) Penciclovir
Ganciclovir {u} (Compound) resembles {v} (Compound) Valaciclovir
Ganciclovir {u} (Compound) binds {v} (Gene) SLC22A8
Ganciclovir {u} (Compound) upregulates {v} (Gene) PAK1
Ganciclovir {u} (Compound) is included by {v} (Pharmacologic Class) DNA Polymerase Inhibitors
Ganciclovir {u} (Compound) downregulates {v} (Gene) CANT1
Ganciclovir {u} (Compound) causes {v} (Side Effect) Creatinine increased
Ganciclovir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Eribulin
Ganciclovir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Irinotecan
Ganciclovir {u} may lead to a major life threatening interaction when taken with {v} Certolizumab pegol
Ganciclovir (Compound) resembles Penciclovir (Compound)
Ganciclovir (Compound) resembles Valaciclovir (Compound)
Ganciclovir (Compound) binds SLC22A8 (Gene)
Ganciclovir (Compound) upregulates PAK1 (Gene)
Ganciclovir (Compound) is included by DNA Polymerase Inhibitors (Pharmacologic Class)
Ganciclovir (Compound) downregulates CANT1 (Gene)
Ganciclovir (Compound) causes Creatinine increased (Side Effect)
Ganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Eribulin
Ganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Irinotecan
Ganciclovir may lead to a major life threatening interaction when taken with Certolizumab pegol